Generation of knockout (KO) cell line models with a loss-of-function mutation is an important method for studying the function of given genes. Compared with traditional gene interference (RNAi) technology, gene knockout (KO) models allow researchers to fully disrupt expression of the target gene, ultimately leading to either complete non-expression or loss of function in proteins. Gene knockout (KO) cell lines enable researchers to study the role of specific genes by comparing the phenotypic differences among the knockout and wildtype cells.
The generation of gene knockout cell lines can be time-consuming and complicated, especially for researchers unfamiliar with the process. Oftentimes, scientists may spend 3-4 months attempting to generate a custom cell line, but end up with an incomplete knockout upon genotyping – significantly setting back research progress.
Cyagen’s Smart-CRISPR™ cell line modeling services enable large fragment excision or accurate mutation(s) – providing knockout cell lines with complete loss-of-function of the target gene.
Our custom cell line modeling services platform features CRISPR-mediated gene editing that is optimally targeted with our proprietary artificial intelligence (AI)-based AlphaKnockout Smart Gene Targeting System - enabling higher knockout (KO) efficiency. We can perform multiple knockout strategies, including frameshift mutation, large fragment knockout, and multiple genes knockout. With CRISPR-Pro technology, researchers can easily solve the problem of residual protein expression seen in RNA interference (RNAi) gene knockdown models.
Our experts have generated 1,000+ cell line models - Cyagen can rapidly generate knockout cell lines for your research using our highly efficient Smart-CRISPR™ platform.
We can perform a variety of knockout (KO) strategies to generate a custom cell line model, including frameshift mutation, large fragment knockout, and multiple genes knockout. We will adopt the best knockout strategy to greatly improve the success rate of target gene knockout and the expression efficiency according to each project's unique requirements.
The unique combination of our highly efficient CRISPR-based technology platform along with extensive experience allows for rapid knockout cell line model generation, up to 2-3 weeks shorter than the conventional timeline.
Upon request, we can deliver homozygous, heterozygous, or negative clones. We can additionally provide professional experiment reports and quality inspection reports.
Classification | Cell Line Name | Abbreviation |
---|---|---|
Blood and lymphatic system |
Mouse monocyte macrophage leukemia cells |
RAW 264.7 |
Human B lymphoblasts |
HMy2.CIR |
|
Human T lymphocyte leukemia cells |
HuT 78 |
|
Human monocytic leukemia |
THP-1 |
|
Human chronic myeloid leukemia cells |
K-562 |
|
Human promyelocytic leukemia cells |
HL-60 |
|
Human leukemia T lymphocyte |
Jurkat, Clone E6-1 |
|
Bone and skin system |
Mouse melanoma cells |
B16 |
Mouse skin melanoma cells |
B16-F10 |
|
Human osteosarcoma cells |
U-2 OS |
|
Human malignant melanoma cells |
A375 |
|
Human fibrosarcoma cells |
HT-1080 |
|
Digestive system |
Mouse colon cancer cells |
CT26.WT |
Human ileocecal carcinoma cells |
HCT-8 |
|
Human colon cancer cell |
HCT 116 |
|
HT-29 |
||
Human colon adenocarcinoma cells |
SW480 |
|
Human colorectal cancer cells |
LoVo |
|
Human esophageal squamous cell carcinoma cells |
KYSE-150 |
|
Human gastric cancer cells |
HGC-27 |
|
Respiratory system |
Mouse lung cancer cells |
LLC |
Hamster lung cells |
V79 |
|
Human normal lung epithelial cells |
BEAS-2B |
|
Large cell lung cancer cell |
NCI-H460 |
|
Human on-small-cell lung carcinoma |
NCI-H1299 |
|
A549 |
||
Human lung squamous cell carcinoma cells |
SK-MES-1 |
|
NCI-H520 |
||
Urinary system |
Mouse glomerular mesangial cells |
SV40 MES 13 |
Rat adrenal pheochromocytoma cells |
PC-12 |
|
Rat renal cells |
NRK |
|
African green monkey kidney cells |
Vero |
|
Rhesus monkey kidney cells |
LLC-MK2 |
|
Human bladder cancer cells |
5637 |
|
Human prostate cancer cells |
PC-3 |
|
Human embryonic kidney cells |
293 Cells, low passage |
|
Human renal cell adenocarcinoma cells |
786-O |
|
ACHN |
||
Brain and nervous system |
Mouse pituitary tumor cells |
AtT-20 |
Rat glioma cells |
C6 |
|
Human glioma cells |
U251 |
|
Human neuroblastoma cells |
SK-N-SH |
|
Endocrine system |
Mouse breast cancer cells |
4T1 |
Human breast cancer cells |
MCF-7 |
|
MDA-MB-231 |
||
Reproductive system |
Hamster ovary cell subline |
CHO-K1 |
Human cervical cancer cells |
Hela |
|
Human ovarian cancer cells |
SK-OV-3 |
|
Circulatory system |
Mouse myoblasts |
C2C12 |
Rat myoblasts |
L6 |
|
Rat cardiomyocytes |
H9c2(2-1) |
Project: Human HCT116 cell PSME3 gene knockout (fragment deletion)
1. gRNA Design
gRNA Site 1: ATACGCTACCTAACATGGCTGGG;
gRNA Site 2: CCAGCATGCAAAATACAATGGGG
2. Primer Synthesis and Plasmid Construction
3. Cell Transfection
Firstly, confirm the optimal electroporation parameters, then transfect the vector into cells by electroporation.
4. Single Cell Clone Screening and Culture
5. PCR and Electrophoresis Identification
Identification Strategy:
6. Sequencing Identification
ATAAACAGAGGATTTAAGACTTTTGTTATGTTTTAGACGC-del;
1809bp--AGTGGCTAATGCCT GTAATCC CACCACTTTGGGAGGCCAA